

# John E Bowen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8900043/john-e-bowen-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47  
papers

4,607  
citations

25  
h-index

49  
g-index

49  
ext. papers

8,595  
ext. citations

39.2  
avg, IF

5.74  
L-index

#	Paper	IF	Citations
47	Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. <i>Cell</i> , <b>2020</b> , 182, 1295-1310.e20	56.2	935
46	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. <i>Cell</i> , <b>2020</b> , 183, 1024-1042.e21	56.2	601
45	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , <b>2021</b> , 184, 2332-2347.e16	56.2	316
44	Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. <i>Nature</i> , <b>2021</b> , 593, 136-141	50.4	376
43	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. <i>Science</i> , <b>2020</b> , 370, 950-957	33.3	314
42	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.. <i>Nature</i> , <b>2021</b> ,	50.4	204
41	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. <i>Science</i> , <b>2021</b> , 373, 648-654	33.3	197
40	Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. <i>Nature</i> , <b>2021</b> , 595, 707-712	50.4	168
39	Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020 <b>2021</b> ,		142
38	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. <i>Nature</i> , <b>2021</b> , 597, 97-102	50.4	118
37	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity.. <i>Nature</i> , <b>2022</b> ,	50.4	95
36	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , <b>2021</b> , 597, 103-108	50.4	94
35	Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. <i>Nature Structural and Molecular Biology</i> , <b>2020</b> , 27, 942-949	17.6	89
34	Broad betacoronavirus neutralization by a stem helix-specific human antibody. <i>Science</i> , <b>2021</b> , 373, 1109-1116	33.3	80
33	Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement.. <i>Science</i> , <b>2022</b> , 375, eabn8652	33.3	71
32	SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies <b>2021</b> ,		69
31	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. <i>Science</i> , <b>2021</b> , eabl8506	33.3	65

30	Structural basis for broad coronavirus neutralization. <i>Nature Structural and Molecular Biology</i> , <b>2021</b> , 28, 478-486	17.6	65
29	Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. <i>Nature</i> , <b>2021</b> , 598, 342-347	50.4	63
28	SARS-CoV-2 immune evasion by variant B.1.427/B.1.429 <b>2021</b> ,		62
27	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> ,	50.4	44
26	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 <b>2021</b> ,		34
25	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , <b>2021</b> , 184, 5432-5447.e16	56.2	34
24	Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding <b>2020</b> ,		33
23	Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants <b>2021</b> ,		31
22	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.. <i>Science</i> , <b>2022</b> , 375, eabm8143	33.3	23
21	SARS-CoV-2 Omicron spike mediated immune escape and tropism shift		23
20	SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses.. <i>Cell</i> , <b>2022</b> ,	56.2	21
19	Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies		18
18	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <b>2021</b> ,		16
17	Structural basis for broad coronavirus neutralization <b>2021</b> ,		14
16	Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody <b>2021</b> ,		14
15	A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery		13
14	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines <b>2021</b> ,		12
13	Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape <b>2021</b> ,		12

12	Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement		11
11	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy.. <i>PLoS Pathogens</i> , <b>2022</b> , 18, e1010248	7.6	7
10	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry <b>2021</b> ,		7
9	SARS-CoV-2 spike conformation determines plasma neutralizing activity. <b>2021</b> ,		6
8	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy <b>2021</b> ,		5
7	Imprinted antibody responses against SARS-CoV-2 Omicron sublineages		5
6	Multivalent designed proteins protect against SARS-CoV-2 variants of concern <b>2021</b> ,		4
5	Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines. <b>2022</b> ,		3
4	ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies		3
3	Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses. <b>2021</b> ,		3
2	Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice.. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabn1252	17.5	3
1	Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail. <b>2022</b> ,		2